Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study shows that clonal haematopoiesis of indeterminate potential (CHIP)-driver mutations in DNMT3A or TET2 are associated with increased medium-term mortality in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation.
The 2-year results of the MITRA-FR trial confirm the 1-year findings showing that addition of percutaneous mitral valve repair to medical treatment does not reduce the risk of death or hospitalization for heart failure compared with medical treatment alone in patients with heart failure and severe secondary mitral regurgitation
The PARAGON-HF trial indicates that sacubitril–valsartan does not have a significant benefit in patients with heart failure with preserved ejection fraction (HFpEF) for reducing hospitalizations for heart failure and death from cardiovascular causes. However, the trial suggests a potential benefit in patients with low left ventricular ejection fraction and in women.
Africa faces many health challenges, many of which are unique to the continent. Although rarely considered an important contributor to premature death in high-income countries, cardiopulmonary disease (CPD) is, for a number of reasons, a common condition affecting Africans at a young age. In addition to recognizing CPD as an important condition, we outline a pragmatic screening protocol for identifying CPD in the African context.
A novel, community-based model of care led by non-physician health workers significantly reduced blood pressure levels and risk of cardiovascular disease.
In the PolyIran study, a fixed-dose polypill strategy was more effective than non-pharmacological interventions in reducing the risk of cardiovascular events.
In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure.
Scientific research drives discoveries and innovations that improve the prevention and management of cardiovascular disease. Cardiovascular research in China is thriving, as evidenced by the increasing number of publications and funding support for projects. However, data collection and the quality of publications require much improvement to propel the research field forward.
The transcription factor FOXP1 downregulates activation of the endothelial NLRP3 inflammasome and suppresses vascular inflammation, protecting against atherosclerosis. Upregulation of FOXP1 expression is a novel anti-atherogenic effect of simvastatin.
A new study shows that the loss of an enzyme in humans during evolution might be a contributing factor to the increased predisposition to atherosclerosis in humans compared with other animals